HC Wainwright Weighs in on NextCure FY2030 Earnings

NextCure, Inc. (NASDAQ:NXTC) – Equities researchers at HC Wainwright issued their FY2030 earnings estimates for shares of NextCure in a report issued on Wednesday, July 15th. HC Wainwright analyst E. Bodnar forecasts that the company will earn ($0.18) per share for the year. HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for NextCure’s current full-year earnings is ($7.90) per share.

NXTC has been the topic of a number of other research reports. Weiss Ratings cut NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, July 7th. Zacks Research raised NextCure from a “strong sell” rating to a “hold” rating in a research report on Thursday, June 11th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $19.00.

NextCure Price Performance

NASDAQ NXTC opened at $6.63 on Thursday. The firm’s fifty day moving average price is $4.59 and its 200 day moving average price is $9.37. NextCure has a 12 month low of $1.55 and a 12 month high of $15.74. The company has a market capitalization of $23.95 million, a price-to-earnings ratio of -0.39 and a beta of 1.42.

NextCure (NASDAQ:NXTC) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($1.87) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.10) by $0.23.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Marshall Wace LLP acquired a new position in shares of NextCure during the 4th quarter valued at about $160,000. Millennium Management LLC purchased a new position in shares of NextCure in the 4th quarter worth $185,000. Geode Capital Management LLC grew its position in NextCure by 18.6% during the fourth quarter. Geode Capital Management LLC now owns 23,157 shares of the company’s stock valued at $329,000 after acquiring an additional 3,636 shares during the period. Renaissance Technologies LLC raised its holdings in NextCure by 18.7% in the fourth quarter. Renaissance Technologies LLC now owns 33,634 shares of the company’s stock valued at $477,000 after buying an additional 5,300 shares during the period. Finally, Boothbay Fund Management LLC acquired a new stake in shares of NextCure in the fourth quarter valued at about $988,000. 42.65% of the stock is currently owned by institutional investors and hedge funds.

NextCure Company Profile

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.